Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

NCT01812252 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome
Secondary Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine (AZC)
DRUG: Decitabine
OTHER: Quality-of-Life Assessment

Sponsor

Fred Hutchinson Cancer Center